Anabolic-Androgenic Ratio: Methodology, Meaning, and Limitations

Research Disclaimer: All compounds described are sold exclusively for in-vitro and laboratory research use. Not for unsupervised use. This content does not constitute medical advice.

The anabolic-androgenic (A:A) ratio is the most commonly cited index of androgen tissue selectivity. It compares a compound's ability to stimulate anabolic tissue growth (muscle: levator ani) relative to androgenic tissue growth (prostate: ventral prostate) versus testosterone propionate as the reference standard. Understanding how this ratio is determined — and its significant methodological limitations — is essential for interpreting androgen pharmacology research.

Table of Contents#

1. Origin of the Anabolic-Androgenic Concept
2. The Hershberger Assay: How the Ratio is Measured
3. Tissue Endpoints: Levator Ani vs. Ventral Prostate
4. A:A Ratio Values Across Compounds
5. Critical Limitations of the Ratio
6. What the A:A Ratio Does and Doesn't Predict
7. Modern Approaches to Selectivity Assessment
8. Research Protocols
9. Key References

Origin of the Anabolic-Androgenic Concept#

The concept of separating anabolic (tissue-building) from androgenic (masculinizing) effects of steroids emerged in the 1930s–1950s when chemists began modifying the testosterone skeleton. The first quantitative method was published by Hershberger et al. (1953) — assaying myotrophic activity of 19-nortestosterone (nandrolone) using the levator ani muscle in castrated rats.

The Hershberger assay became:

• The industry standard for screening new androgens
• Adopted by the OECD as Test Guideline 441 (Tier 1 endocrine disruptor screen)
• The basis for all historical A:A ratio values in the androgen pharmacology literature

The Hershberger Assay: How the Ratio is Measured#

Standard protocol (OECD TG 441)#

Animals:

• Adult male Sprague-Dawley or Wistar rats
• Age: 10–12 weeks
• Castrated (bilateral orchiectomy) ≥7 days before treatment

Treatment:

• Reference: testosterone propionate (TP) 0.4 mg/kg/day SC for 10 days
• Test compound: SC injection (dose selected for equivalent bioavailability where known)
• Vehicle control: oil only

Harvest:

• Day 11 (24h after final injection)
• Tissues weighed: levator ani muscle, ventral prostate, seminal vesicles, Cowper's glands, glans penis
• All weights expressed as mg/100g body weight (normalize for body weight differences)

Calculating the A:A ratio#

For each compound:

Anabolic response = (levator ani weight, test) / (levator ani weight, TP)
Androgenic response = (ventral prostate weight, test) / (ventral prostate weight, TP)
A:A ratio = Anabolic response / Androgenic response

Where TP at 0.4 mg/kg/day × 10 days defines 1.0:1.0 by convention.

Tissue Endpoints: Levator Ani vs. Ventral Prostate#

Levator ani muscle (anabolic endpoint)#

The levator ani is an ideal anabolic endpoint because:

• It is highly androgen-sensitive (high AR expression)
• It is easily dissected and weighed
• It has low 5α-reductase expression → it responds to the parent androgen (not the 5α-reduced metabolite) → makes it suitable for measuring direct AR activation without the 5α-reductase amplification that occurs in prostate

After castration:

• Levator ani weight falls ~40–60% within 2 weeks (high androgen-dependence)
• Testosterone or anabolic steroids → dose-dependent restoration

Ventral prostate (androgenic endpoint)#

The ventral prostate is an ideal androgenic endpoint because:

• It is highly androgen-sensitive
• It has very high 5α-reductase type 2 expression
• Testosterone → DHT in prostate → amplified signal
• Nandrolone → DHN in prostate → attenuated signal
• Therefore, the prostate endpoint differentiates compounds by their 5α-reductase substrate profile

After castration:

• Ventral prostate weight falls ~80–90% within 2 weeks
• Very sensitive to androgen exposure

A:A Ratio Values Across Compounds#

The following values are compiled from the historical literature (primarily 1950s–1980s assays; some variation exists across labs):

Critical Limitations of the Ratio#

Limitation 1: The assay is rodent-specific#

The rat levator ani and ventral prostate have specific 5α-reductase and AR expression patterns. Human skeletal muscle (deltoid, quadriceps) and prostate have different 5α-reductase type/level profiles. The A:A ratio measured in rats does not directly translate to humans.

Example: finasteride (5α-reductase type 2 inhibitor) eliminates DHT in prostate → reduces testosterone's A:A-equivalent androgenicity in human prostate. This is not captured in the rat Hershberger assay unless finasteride is co-administered.

Limitation 2: The ratio depends on dose#

The A:A ratio is NOT constant across doses:

• At very high doses, many compounds saturate AR in both tissues → A:A ratio converges toward 1.0 as both tissues are maximally stimulated
• At low doses near EC50: the A:A ratio reflects the true tissue selectivity difference
• Most literature values are measured at a single dose → may not represent the full dose-response A:A profile

Limitation 3: Levator ani is atypical muscle#

The levator ani is a perineal muscle with mixed striated/smooth muscle properties and extraordinarily high AR expression. It is not representative of large locomotor muscles (quadriceps, gastrocnemius) that would be relevant for therapeutic muscle wasting or athletic performance applications.

Limitation 4: Ventral prostate is castration-atrophied#

The ventral prostate in a castrated rat is an extremely androgen-sensitive tissue in a maximum-deprivation state. Re-stimulation from zero provides a very sensitive androgenic signal. In the intact male with normal androgen tone, the prostate response to a test compound would be different.

Limitation 5: Metabolic differences are not controlled#

The assay does not control for:

• Species-specific differences in ester hydrolysis rate
• Compound-specific plasma protein binding differences (SHBG binding varies)
• First-pass metabolism differences between compounds

Limitation 6: Prostate endpoint is the wrong clinical target#

In modern androgens research, prostate size is not the only androgenic concern:

• Androgenic alopecia, acne, seborrhea (skin/scalp), virilization in females
• These are not captured by the ventral prostate endpoint

What the A:A Ratio Does and Doesn't Predict#

What it DOES provide#

• A useful relative ranking of compounds for tissue selectivity within the rat Hershberger assay
• A standardized, reproducible screening tool for endocrine disruptors (OECD TG 441)
• Historical comparability (decades of data use the same assay → allows cross-compound comparisons)
• A guide for which compounds to prioritize for further development

What it DOES NOT predict#

• Absolute human therapeutic windows
• Prostate cancer risk (not established from Hershberger data alone)
• Hair loss, acne, or other androgenic effects in humans
• Performance advantage in athletes (anabolic in rat ≠ performance in human)
• Safety or efficacy in human therapeutic settings

Modern Approaches to Selectivity Assessment#

Beyond the Hershberger A:A ratio, modern androgen selectivity assessment includes:

1. In vitro coactivator recruitment assays: Compound → AR → coactivator peptide binding (AlphaScreen or HTRF format) → tissue-specific coactivator profiles reveal selectivity between tissues expressing different coactivators

2. Genome-wide gene expression profiling: Compare compound X-treated muscle vs. prostate (primary human cells or organoids) → identify tissue-specific gene expression patterns → predict selectivity in human context

3. 3D human organoid models: Prostate organoids + skeletal muscle bundles → can test compounds in human tissue context with more translational relevance

4. Transgenic reporter mice: Tissue-specific ARE-luciferase reporters → measure AR activation in vivo in specific tissues non-invasively (bioluminescence imaging)

These approaches complement rather than replace the Hershberger assay — the assay remains the regulatory standard (OECD TG 441) for endocrine disruptor screening.

Research Protocols#

Standard Hershberger assay (OECD TG 441)#

Dose-response A:A calculation#

Run the assay at 4+ doses to construct full dose-response curves:

• Plot levator ani weight vs. dose → fit 4-PL curve → extract ED50 (anabolic)
• Plot ventral prostate weight vs. dose → fit 4-PL curve → extract ED50 (androgenic)
• A:A selectivity index = ED50(androgenic) / ED50(anabolic)
• A higher quotient = more anabolic selectivity at the EC50 level

Key References#

1. Hershberger LG, et al. (1953). "Myotrophic activity of 19-nortestosterone and other steroids determined by modified levator ani muscle method." Proceedings of the Society for Experimental Biology and Medicine, 83(1):175–180.

2. OECD Test Guideline 441. (2009). "Hershberger Bioassay in Rats." Organisation for Economic Co-operation and Development.

3. Gao W, et al. (2005). "Selective androgen receptor modulators (SARMs): current knowledge and clinical applications." Sexual Medicine Reviews, 3(2):67–82.

4. Saartok T, et al. (1984). "Relative binding affinity of anabolic-androgenic steroids." Endocrinology, 114(6):2100–2106.

Research Use Only: All compounds are sold exclusively for in-vitro research and laboratory use. Not for unsupervised use. JuicedPharma does not provide medical advice.

Published by JuicedPharma Research Team · September 2026 · Category: Research Protocols & Science